MAPT and Alzheimer disease: Advanced techniques for detecting plasma Aβ42/Aβ40 [19–21], p-Tau [22–28], astrocyte reactivity [29–31], and axonal degeneration [32, 33] suggest plasma biomarkers have great potential for diagnosing AD [34, 35].